Opinion statement
Paradoxical embolization is a rare but well-recognized cause of stroke. Some studies have suggested a link between patent foramen ovale (PFO) and a higher risk of ischemic stroke through this mechanism. PFO is more commonly seen in patients with cryptogenic stroke, but a clear causative relationship between the two is not well established. Other anatomic features associated with a PFO could increase the risk of a recurrent stroke, including an atrial septal aneurysm (ASA), a large PFO, and spontaneous right-to-left shunt at rest. An underlying hypercoagulable state should be ruled out if a PFO is found in a patient with a stroke or transient ischemic attack who has no other identifiable source. Options for secondary prevention in these patients include antiplatelet therapy, anticoagulation, and surgical or endovascular closure. Studies have not shown any advantage of warfarin over aspirin. Surgical closure is a less favorable option because of its high perioperative risks. To date, retrospective studies show variable results of endovascular closure for prevention of stroke. Several randomized prospective studies currently under way are expected to conclusively answer this question. Until these data is available, antiplatelet therapy remains the first-line treatment and endovascular closure should be considered in selected cases.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Fox ER, Picard MH, Chow CM, et al.: Interatrial septal mobility predicts larger shunts across patient foramen ovale: an analysis with transmitral Doppler scanning. Am Heart J 2003, 145:730–736.
Meissner I, Whisnant JP, Khandheria BK, et al.: Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc 1999, 74:862–869.
Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984, 59:17–20.
Webster MW, Chancellor AM, Smith HJ, et al.: Patent foramen ovale in young stroke patients. Lancet 1988, 2(8601):11–12.
Overell JR, Bone I, Lees KR: Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000, 55(8):1172–1179.
Handke M, Harloff A, Olschewski M, et al.: Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 2007, 357:2262–2268.
Petty GW, Khandheria BK, Meissner I, et al.: Population-based study of the relationship between patent foramen ovale and cerebrovascular ischemic events. Mayo Clin Proc 2006, 81:602–608.
Thaler DE, Saver JL: Cryptogenic stroke and patent foramen ovale. Curr Opin Cardiol 2008, 23:537–544.
Caputi L, Carriero MR, Falcone C, et al.: Transcranial Doppler and transesophageal echocardiography: comparison of both techniques and prospective clinical relevance of transcranial Doppler in patent foramen ovale detection. J Stroke Cerebrovasc Dis 2009, 18:343–348.
Homma S, Sacco RL: Patent foramen ovale and stroke [review]. Circulation 2005, 112:1063–1072.
Mas JL, Arquizan C, Lamy C, et al.: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345(24):1740–1746.
Homma S, Sacco RL, Di Tullio MR, et al.: Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002, 105:2625–2631.
Bogousslavsky J, Garazi S, Jeanrenaud X, et al.: Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 1996, 46:1301–1305.
Wechsler LR: PFO and stroke: What are the data? Cardiol Rev 2008, 16:53–57.
NMT Medical announces preliminary results of CLOSURE I PFO/stroke trial [news release]. NMT Medical, Inc.; June 17, 2010. http://www.snl.com/irweblinkx/file.aspx?IID=4148066&FID=9712903. Accessed August 19, 2010.
Wohrle J: Closure of patent foramen ovale after cryptogenic stroke. Lancet 2006, 368:350–352.
Staubach S, Steinberg DH, Zimmermann W, et al.: New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv 2009, 74(6):889–895.
Tsilimingas NB, Reiter B, Kodolitsch YV, et al.: Surgical revision of an uncommonly dislocated self-expanding Amplatzer septal occluder device. Ann Thorac Surg 2004, 78:686–687.
Goldstein JA, Beardslee MA, Xu H, et al.: Infective endocarditis resulting from CardioSEAL closure of a patent foramen ovale. Catheter Cardiovasc Interv 2002, 55:217–220. discussion 221.
Wertman B, Azarbal B, Riedl M, Tobis J: Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol 2006, 47:1226–1227.
Anzai H, Child J, Natterson B, et al.: Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004, 93:426–431.
Krumsdorf U, Ostermayer S, Billinger K, et al.: Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1, 000 consecutive patients. J Am Coll Cardiol 2004, 43:302–309.
Dorenbeck U, Simon B, Skowasch D, et al.: Cerebral embolism with interventional closure of symptomatic patent foramen ovale: an MRI-based study using diffusion-weighted imaging. Eur J Neurol 2007, 14:451–454.
Taaffe M, Fischer E, Baranowski A, et al.: Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder). Am J Cardiol 2008, 101:1353–1358.
Guffi M, Bogousslavsky J, Jeanrenaud X, et al.: Surgical prophylaxis of recurrent stroke in patients with patent foramen ovale: a pilot study. J Thorac Cardiovasc Surg 1996, 112:260–263.
Devuyst G, Bogousslavsky J, Ruchat P, et al.: Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology 1996, 47:1162–1166.
Dearani JA, Baran US, Danielson GK, et al.: Surgical patent foramen ovale closure for prevention of paradoxical embolism: related cerebrovascular ischemic events. Circulation 1999, 100(suppl II):II-171–II-175.
Walpoth NB, Habermacher K, Moarof I, et al.: Device-less patent foramen ovale closure by radiofrequency thermal energy. Swiss Med Wkly 2008, 138(7–8):108–113.
Mullen MJ, Hildick-Smith D, De Giovanni JV, et al.: BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation 2006, 114(18):1962–1967.
Lechat P, Mas JL, Lascault G, et al.: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988, 318:1148–1152.
Di Tullio M, Sacco RL, Gopal A, et al.: Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992, 117:461–465.
Hausmann D, Mugge A, Becht I, et al.: Diagnosis of patent foramen ovale by transesophageal echocardiography and association with cerebral and peripheral embolic events. Am J Cardiol 1992, 70:668–672.
Cabanes L, Mas JL, Cohen A, et al.: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993, 24:1865–1873.
Disclosure
Dr. Wechsler has received consulting fees from Abbott Vascular, Lundbeck, and Ferrer. No other potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jumaa, M.A., Wechsler, L.R. Management of Patent Foramen Ovale and Stroke. Curr Treat Options Neurol 12, 483–491 (2010). https://doi.org/10.1007/s11940-010-0097-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-010-0097-2